1. P. Goldstraw, K. Chansky, J. Crowley, R. Rami-Porta, H. Asamura, W.E. Eberhardt, A.G. Nicholson, P. Groome, A. Mitchell, V. Bolejack, S. International Association for the Study of Lung Cancer, A.B. Prognostic Factors Committee, I. Participating, S. International Association for the Study of Lung Cancer, B. Prognostic Factors Committee Advisory, I. Participating, The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol 11(1) (2016) 39-51.
2. W. Shalata, B.M. Jacob, A. Agbarya, Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future, Cancers (Basel) 13(16) (2021).
3. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J. Clin. Oncol.,2008
4. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial;Douillard;Lancet Oncol.,2006
5. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation;Douillard;J. Thorac. Oncol.,2010